AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 101 min read$MD

Pediatrix Medical Group (NYSE: MD) director plans Rule 144 stock sale

Pediatrix Medical Group (MD) director Laura Linynsky plans to sell 6,000 shares under Rule 144, acquired through stock plan activity. Merrill Lynch is the broker for the transaction, with the Form 144 notice signed on September 10, 2026.

Original reporting
stocktitan.net
Published Sep 10, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$MD
Neutral
high confidence
Mentioned
$MD
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$MDNeutralLow
01

Why it matters

The filing adds a modest supply of MD shares, but the amount is unlikely to affect price or sentiment.

02

Market read

A routine insider sale filing with limited market impact.

03

What to watch

Potential future sales if the director holds more restricted shares.

Relevance 4/10Novelty 4/10Timing: September 10, 2026 (today)

Background

Form 144 filings are required when insiders intend to sell restricted shares, providing transparency to the market.

Company-level read

Ticker impact

$MDNeutralHigh confidence
Context

Director Laura Linynsky filed a Form 144 indicating a planned sale of up to 6,000 MD shares.

Expected impact

Limited downward pressure; unlikely to move price materially.

Evidence & confidence

The filing is a primary disclosure but the volume (~$150k) is trivial for a mid‑cap stock.

Market effects

Sector

Minimal impact on the healthcare services sector.

Regional

No significant effect on regional markets.

Global

Insignificant on a global scale.

Counterpoint

What could challenge this read

The sale could be a signal of insider concern, but size is too small to matter.

Key entities

  • Director
    Laura Linynsky

    MD director planning the share sale.

  • Broker
    Merrill Lynch

    Designated broker for the proposed transaction.

Read at source← All news

Related articles

AUG 11
$MDMedAI 8/10

Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.

fool.com6 min
AUG 4
$MDMed

Pediatrix Medical Group Reports Second Quarter Results

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G

SEC EDGAR 8-K6 min
JUL 15
$MDMed

Pediatrix Medical Group Provides Second Quarter Update

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Provides Second Quarter Update FORT LAUDERDALE, Fl

SEC EDGAR 8-K3 min
MAY 27
$MDHighAI 9/10

Does Pediatrix Medical Group (MD) Stock Look Better After Q1 Report?

Pediatrix Medical Group (NYSE:MD) reported Q1 2026 results on May 5. Revenue rose to $476.2 million from $458.4 million a year earlier, beating the $465.7 million analyst estimate, according to the company. Adjusted EBITDA increased to $58.2 million from $49.2 million. Adjusted EPS was $0.44 vs. $0.33 a year ago, above the $0.38 estimate. The company expects full-year 2026 adjusted EBITDA of $280–$300 million.

finance.yahoo.com5 min